Sign In
Buy TRCK
$0.640
+0 (+0%)
At Close: Jun 03, 2026
Advantage Energy: La Niña On Track
09:55am, Sunday, 18'th Jan 2026
Advantage Energy stands to benefit from La Niña-driven cold weather. AAVVF remains heavily exposed to natural gas. Rising natural gas demand may improve returns on new wells.
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWS
SecureAlert (OTCMKTS:TRCK) & BigBear.ai (NYSE:BBAI) Critical Contrast
02:28am, Monday, 12'th Jan 2026
BigBear.ai (NYSE: BBAI - Get Free Report) and SecureAlert (OTCMKTS:TRCK - Get Free Report) are both computer and technology companies, but which is the superior investment? We will contrast the two bu
Wabtec Stays On Track For A Strong 2026
11:41pm, Thursday, 08'th Jan 2026
Wabtec Corporation remains a Buy, supported by robust backlog growth and improving margins across both freight and transit divisions. WAB's $386 million NYC hybrid locomotive order and international c
The Dividend Aristocrats No One's Talking About (And Their 30+ Year Track Records)
03:40pm, Thursday, 08'th Jan 2026
Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among ot
PlusAI on Track to Launch Factory-Built Commercial Autonomous Trucks Next Year
07:00am, Thursday, 08'th Jan 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #Autonomousdriving--PlusAI, a leader in AI software for autonomous trucks, today provided an update on its commercial readiness metrics, demonstrating continued
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (Nasdaq: MOBX, “Mobix Labs” or the “Company”), a leading provider of advanced connectivity solutions, today announced the pr
Nvidia's Rubin Chips on Track, CEO Huang Says
01:59am, Tuesday, 06'th Jan 2026
Nvidia's highly anticipated Rubin data center processors are in production and customers will soon be able to try out the technology, according to Chief Executive Officer Jensen Huang. Meanwhile, Adva
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
11:31am, Monday, 05'th Jan 2026
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in Chi
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
3D Systems Accelerates Growth in Aerospace & Defense with Strategic Investments and Projected Leadership Position
07:30am, Monday, 05'th Jan 2026
Aerospace & Defense on Track to Become Company's Largest Industrial Business in 2026, Supported by Ongoing Investments and Favorable U.S. Policy Tailwinds Aerospace & Defense on Track to Become Compan
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
07:00am, Monday, 05'th Jan 2026
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fas
Shoe Carnival's Transformation Into Shoe Station Is Still On Track
10:43pm, Tuesday, 30'th Dec 2025
Shoe Carnival is executing a turnaround by converting stores to the higher-margin Shoe Station brand, targeting middle-income consumers. Short-term headwinds from rebranding are offset by a $50 millio
Track Group Reports Fiscal 2025 Financial Results
11:00am, Friday, 19'th Dec 2025
NAPERVILLE, Ill., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Track Group, Inc. (OTCQB: TRCK), a global leader in offender tracking and monitoring services, today announced financial results for its fiscal year
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
11:55am, Thursday, 18'th Dec 2025
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales.
